⌕
BeOne Medicines · ONC · Nasdaq
Tenet 64 · Solid
Compare
$411.29−1.26%At closeTenet 64 · Solid
$411.29−5.25 (−1.26%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

BeOne Medicines (ONC) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Defense WorldNov 9, 2026 · 04:18 ET
BeOne Medicines Q3 Earnings Call Highlights

BeOne Medicines (NASDAQ: ONC) raised its 2026 revenue and operating income forecasts after third-quarter sales of its cancer drug BRUKINSA topped $1 billion in the United States for the first time. The company reported t…

● Defense WorldNov 6, 2026 · 02:40 ET
BeOne Medicines (NASDAQ:ONC) Hits New 52-Week High After Better-Than-Expected Earnings

Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ONC - Get Free Report) hit a new 52-week high on Thursday following a better than expected earnings announcement. The stock traded as high as $407.00 and last trade…

● Zacks Investment ResearchNov 5, 2026 · 18:30 ET
Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with …

● Seeking AlphaNov 5, 2026 · 16:24 ET
BeOne Medicines AG (ONC) Q3 2026 Earnings Call Transcript

BeOne Medicines AG ( ONC ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Daniel Maller - Vice President of Investor Relations John Oyler - Co-Founder, Executive Chairman & CEO Aaron Rosenberg - …

● Business WireNov 5, 2026 · 06:00 ET
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter…

● Business WireNov 4, 2026 · 09:13 ET
U.S. FDA Grants Priority Review to BeOne Medicines' BRUKINSA Combination in First-Line Mantle Cell Lymphoma

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted …

● Zacks Investment ResearchNov 3, 2026 · 10:16 ET
Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for…

● Business WireNov 3, 2026 · 06:01 ET
BeOne Medicines to Present at the Jefferies Global Healthcare Conference

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Confere…

● Zacks Investment ResearchNov 3, 2026 · 05:26 ET
New Strong Buy Stocks for November 3rd

HPE, AER, UGP, ONC and BWFG have been added to the Zacks Rank #1 (Strong Buy) List on November 3, 2026.…

● Defense WorldOct 31, 2026 · 04:43 ET
BeOne Medicines (NASDAQ:ONC) Stock: Insider Xiaodong Wang Sells 31,028 Shares

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ONC - Get Free Report) insider Xiaodong Wang sold 31,028 shares of the firm's stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of …

● Business WireOct 24, 2026 · 04:15 ET
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicine…

● Business WireOct 23, 2026 · 10:15 ET
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis …

● Seeking AlphaOct 23, 2026 · 08:46 ET
BeOne Medicines: Brukinsa And Tevimbra Face A High Bar

BeOne Medicines AG is a fast-growing oncology company and a Wall Street favorite. Tevimbra, its PD-1 inhibitor, helped drive growth, with Q2 revenue rising 10.8% QoQ and 18.1% YoY to $228.5 million. BeOne's rich pipeline…

● Business WireOct 22, 2026 · 06:01 ET
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, …

● Business WireOct 19, 2026 · 06:00 ET
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor port…

● Defense WorldOct 18, 2026 · 04:09 ET
BeOne Medicines (NASDAQ:ONC) Insider Sells $10,890,166.73 in Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ONC - Get Free Report) insider Xiaodong Wang sold 31,027 shares of BeOne Medicines stock in a transaction on Tuesday, October 13th. The shares were sold at an average price o…

● Zacks Investment ResearchOct 15, 2026 · 13:00 ET
All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy

BeOne Medicines Ltd. - Sponsored ADR (ONC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).…

● Zacks Investment ResearchOct 15, 2026 · 06:05 ET
New Strong Buy Stocks for October 15th

KMX, ACIC, ONC, ODD and WES have been added to the Zacks Rank #1 (Strong Buy) List on October 15, 2026.…

● Defense WorldOct 12, 2026 · 01:59 ET
Comparing Aurora Cannabis (NASDAQ:ACB) & BeOne Medicines (NASDAQ:ONC)

BeOne Medicines (NASDAQ: ONC - Get Free Report) and Aurora Cannabis (NASDAQ: ACB - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the streng…

● Investors Business DailyOct 1, 2026 · 12:44 ET
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points

Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter.…

● Defense WorldOct 1, 2026 · 04:15 ET
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Stock Has Consensus Target Price of $402.71

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ONC - Get Free Report) has earned a consensus recommendation of "Buy" from the seventeen ratings firms that are currently covering the firm, MarketBeat reports. Two analysts …

● Defense WorldSep 28, 2026 · 08:15 ET
Head-To-Head Analysis: BeOne Medicines (NASDAQ:ONC) versus NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) and BeOne Medicines (NASDAQ: ONC - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the streng…

● Business WireSep 1, 2026 · 06:00 ET
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Health…

● Business WireAug 31, 2026 · 15:00 ET
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand acce…

● Business WireAug 31, 2026 · 06:00 ET
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2…

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.